Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evidence of Zika Virus Reinfection by Genome Diversity and Antibody Response Analysis, Brazil.
da Costa Castilho M, de Filippis AMB, Machado LC, de Lima Calvanti TYV, Lima MC, Fonseca V, Giovanetti M, Docena C, Neto AM, Bôtto-Menezes CHA, Kara EO, de La Barrera R, Modjarrad K, Giozza SP, Pereira GF, Alcantara LCJ, Broutet NJN, Calvet GA, Wallau GL, Franca RFO. da Costa Castilho M, et al. Among authors: modjarrad k. Emerg Infect Dis. 2024 Feb;30(2):310-320. doi: 10.3201/eid3002.230122. Emerg Infect Dis. 2024. PMID: 38270216 Free PMC article.
Zika Virus in Rectal Swab Samples.
Bôtto-Menezes CHA, Neto AM, Calvet GA, Kara EO, Lacerda MVG, Castilho MDC, Ströher U, Antunes de Brito CA, Modjarrad K, Broutet N, Brasil P, Bispo de Filippis AM, Franca RFO; ZIKABRA Study Team. Bôtto-Menezes CHA, et al. Among authors: modjarrad k. Emerg Infect Dis. 2019 May;25(5):951-954. doi: 10.3201/eid2505.180904. Emerg Infect Dis. 2019. PMID: 31002058 Free PMC article.
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.
Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, Maddur MS, Tompkins KR, Martinez LT, Cai H, Ramos M, Mensah S, Cumbia B, Falcao L, McKeen AP, Chang JS, Fennell KF, Huynh KW, McLellan TJ, Sahasrabudhe PV, Chen W, Cerswell M, Garcia MA, Li S, Sharma R, Li W, Dizon KP, Duarte S, Gillett F, Smith R, Illenberger DM, Efferen KS, Vogel AB, Anderson AS, Şahin U, Swanson KA. Modjarrad K, et al. NPJ Vaccines. 2024 Nov 20;9(1):229. doi: 10.1038/s41541-024-01013-9. NPJ Vaccines. 2024. PMID: 39567521 Free PMC article.
Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study.
Tiamiyu AB, Adegbite OA, Freides O, Frndak S, Mohammed SS, Broach E, Lombardi K, Anyebe V, Akiga R, Okeke NC, Feyisayo JE, Ugwuezumba O, Akinde C, Osuji A, Agu N, Analogbei T, Ekweremadu C, Bartolanzo D, Prins P, Fan Y, Emekaili D, Abah F, Chiwetelu V, Dike P, Isaiah E, Ayogu M, Ogunkelu E, Agbaim UC, Bukunmi A, Adamu Y, Mebrahtu T, Zuppe A, Johnston M, Modjarrad K, Meri H, Parker Z, Akinwale E, McCauley MD, Schluck G, King DB, Eller LA, Okeji N, Ayemoba OR, Collins ND, Iroezindu MO, Hakre S; EID023 Lassa study team. Tiamiyu AB, et al. Among authors: modjarrad k. BMC Infect Dis. 2024 Oct 8;24(1):1118. doi: 10.1186/s12879-024-09954-1. BMC Infect Dis. 2024. PMID: 39375602 Free PMC article.
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.
Martinez EJ, Chang WC, Chen WH, Hajduczki A, Thomas PV, Jensen JL, Choe M, Sankhala RS, Peterson CE, Rees PA, Kimner J, Soman S, Kuklis C, Mendez-Rivera L, Dussupt V, King J, Corbett C, Mayer SV, Fernandes A, Murzello K, Cookenham T, Hvizdos J, Kummer L, Hart T, Lanzer K, Gambacurta J, Reagan M, Duso D, Vasan S, Collins ND, Michael NL, Krebs SJ, Gromowski GD, Modjarrad K, Kaundinya J, Joyce MG. Martinez EJ, et al. Among authors: modjarrad k. iScience. 2024 Aug 23;27(10):110624. doi: 10.1016/j.isci.2024.110624. eCollection 2024 Oct 18. iScience. 2024. PMID: 39351195 Free PMC article.
Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
Pagnon A, Carre C, Aguirre M, Chautard E, Gimenez S, Raynal F, Feroldi E, Scott P, Modjarrad K, Vangelisti M, Mantel N. Pagnon A, et al. Among authors: modjarrad k. EBioMedicine. 2024 Oct;108:105332. doi: 10.1016/j.ebiom.2024.105332. Epub 2024 Sep 17. EBioMedicine. 2024. PMID: 39293214 Free PMC article. Clinical Trial.
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial.
Modjarrad K, Scott PT, McCauley M, Ober-Shepherd B, Sondergaard E, Amare MF, Parikh AP, Omar B, Minutello AM, Adhikarla H, Wu Y, P AR, Delore V, Mantel N, Morrison MN, Kourbanova KS, Martinez ME, Guzman I, Greenleaf ME, Darden JM, Koren MA, Hamer MJ, Lee CE, Hutter JN, Peel SA, Robb ML, Vangelisti M, Feroldi E. Modjarrad K, et al. Lancet Infect Dis. 2024 Dec;24(12):1393-1402. doi: 10.1016/S1473-3099(24)00406-7. Epub 2024 Aug 14. Lancet Infect Dis. 2024. PMID: 39153488 Clinical Trial.
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.
Gayed J, Bangad V, Xu X, Mensa F, Cutler M, Türeci Ö, Şahin U, Modjarrad K, Swanson KA, Anderson AS, Gurtman A, Kitchin N; C4591054 Study Group. Gayed J, et al. Among authors: modjarrad k. Vaccines (Basel). 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734. Vaccines (Basel). 2024. PMID: 39066372 Free PMC article.
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, Bryant C, McGuire S, Kennedy J, Chen WH, Hajduczki A, Mdluli T, Valencia-Ruiz A, Amare MF, Matyas GR, Rao M, Rolland M, Mascola JR, De Rosa SC, McElrath MJ, Montefiori DC, Serebryannyy L, McDermott AB, Peel SA, Collins ND, Joyce MG, Robb ML, Michael NL, Vasan S, Modjarrad K; EID-030 Study Group. Ober Shepherd BL, et al. Among authors: modjarrad k. Lancet Microbe. 2024 Jun;5(6):e581-e593. doi: 10.1016/S2666-5247(23)00410-X. Epub 2024 May 15. Lancet Microbe. 2024. PMID: 38761816 Free article. Clinical Trial.
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study.
Bakri FG, Mukattash HH, Esmeiran H, Schluck G, Storme CK, Broach E, Mebrahtu T, Alhawarat M, Valencia-Ruiz A, M'Hamdi O, Malia JA, Hassen Z, Shafei MMS, Alkhatib AY, Gazo M, Jaradat SA, Gomez Y, McGeehon S, McCauley MD, Moreland SC, Darden JM, Amare M, Crowell TA, Vasan S, Michael NL, Ake JA, Modjarrad K, Scott PT, Peel SA, Hakre S; RV505 study group. Bakri FG, et al. Among authors: modjarrad k. Int J Infect Dis. 2024 Aug;145:107079. doi: 10.1016/j.ijid.2024.107079. Epub 2024 Apr 30. Int J Infect Dis. 2024. PMID: 38697607 Free article.
135 results